The study described in the present application will test the hypothesis that insulin mediated
facilitation of memory in Alzheimer's disease (AD) is achieved through enhanced glutamatergic
neurotransmission due to improvements in cerebral glucose metabolism. The effect of a single
dose of intranasal insulin on memory and cerebral glutamate concentrations in adults with
mild AD or amnestic mild cognitive impairment (aMCI), the presumed prodromal phase of AD will
be studied. Successful completion of this study may set the stage for a larger-scale
treatment trial of intranasal insulin for adults with memory disorders. However, the use of
insulin in this manner at this point in time is purely experimental.